ASTROTECH Revenue Soars 773% on Grants, Net Loss Widens to $3.47M

TL;DR

ASTC's revenue exploded thanks to grants, but they're still bleeding cash and losing more money, so don't expect profitability anytime soon.

AI Summary

ASTROTECH Corp (ASTC) reported a significant increase in revenue for the three months ended September 30, 2025, reaching $297,000, a substantial rise from $34,000 in the same period of 2024. This 773.5% revenue growth was primarily driven by $234,000 in grant revenue and $20,000 in training revenue, neither of which were present in the prior year. Despite this revenue surge, the company's net loss widened to $3.465 million, up from $3.278 million in Q3 2024, reflecting increased operating expenses. Selling, general, and administrative expenses rose to $1.780 million from $1.688 million, while research and development costs remained stable at $1.944 million. Cash and cash equivalents decreased from $3.100 million at June 30, 2025, to $2.646 million at September 30, 2025, and total current assets declined from $21.975 million to $18.193 million. The company is actively commercializing its AMS Technology through subsidiaries like 1stDetect, AgLAB, and BreathTech, and recently entered into a new lease for a 17,628 square foot Metric Facility in Austin, Texas, with a total contractual base rent obligation of approximately $3.0 million.

Why It Matters

ASTC's dramatic revenue increase, largely from grant funding, signals potential for its mass spectrometry technology but masks persistent operational losses. For investors, the widening net loss and declining cash reserves are critical concerns, indicating that current revenue streams aren't yet sufficient to achieve profitability. Employees and customers of subsidiaries like 1stDetect and AgLAB might see this as a mixed signal, with R&D continuing but financial stability remaining elusive. In a competitive market for advanced detection and analysis technologies, ASTC's ability to convert grant-funded development into sustainable product sales will determine its long-term viability and market position.

Risk Assessment

Risk Level: high — The company reported a net loss of $3.465 million for the quarter, an increase from $3.278 million in the prior year, and cash and cash equivalents decreased by $454,000 to $2.646 million. This continued net loss and declining cash position, despite a significant revenue increase, indicate a high burn rate and ongoing financial instability.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor future filings closely for signs of sustainable revenue growth from product sales, not just grants, and a clear path to profitability before considering any investment.

Financial Highlights

debt To Equity

0.22

revenue

$297,000

operating Margin

-1190.6%

total Assets

$23.240 million

total Debt

$4.153 million

net Income

-$3.465 million

eps

-$2.07

gross Margin

63.3%

cash Position

$2.646 million

revenue Growth

+773.5%

Revenue Breakdown

Key Numbers

• $297,000 — Revenue (Increased from $34,000 in Q3 2024, a 773.5% increase)
• $3.465 million — Net Loss (Widened from $3.278 million in Q3 2024)
• $2.646 million — Cash and Cash Equivalents (Decreased from $3.100 million at June 30, 2025)
• $18.193 million — Total Current Assets (Decreased from $21.975 million at June 30, 2025)
• $234,000 — Grant Revenue (Primary driver of revenue increase in Q3 2025)
• $1.780 million — Selling, General and Administrative Expenses (Increased from $1.688 million in Q3 2024)
• $1.944 million — Research and Development Expenses (Stable compared to $1.949 million in Q3 2024)
• 1,758,953 — Common Shares Outstanding (As of November 11, 2025)

Key Players & Entities

• ASTROTECH Corp (company) — registrant
• 1stDetect Corporation (company) — manufacturer of explosives and narcotics trace detectors
• AgLAB, Inc. (company) — developing mass spectrometers for hemp and cannabis market
• BreathTech Corporation (company) — developing breath analysis tool for VOC metabolites
• Pro-Control, Inc. (company) — applying AMS Technology in industrial process control
• EN-SCAN, Inc. (company) — developing environmental testing and monitoring solutions
• Securities and Exchange Commission (regulator) — filing oversight
• NASDAQ Stock Market, LLC (company) — exchange where ASTC common stock is registered

FAQ

Risk Factors

• Widening Net Loss [high — financial]: The company's net loss widened to $3.465 million in Q3 2025 from $3.278 million in Q3 2024, despite a significant revenue increase. This indicates that the growth in revenue is not yet translating into profitability and that operating expenses are increasing.
• Decreasing Cash Position [high — financial]: Cash and cash equivalents decreased from $3.100 million to $2.646 million during Q3 2025. This reduction, coupled with increasing operating expenses, raises concerns about the company's short-term liquidity.
• Declining Current Assets [medium — financial]: Total current assets fell from $21.975 million to $18.193 million in Q3 2025. This decline is largely due to a decrease in short-term investments from $15.108 million to $11.290 million.
• Dependence on Grant Revenue [high — operational]: The substantial revenue growth of 773.5% was driven by $234,000 in grant revenue, a source that may not be sustainable or predictable. The company's ability to generate revenue from its commercialization efforts is yet to be proven at scale.
• High Operating Expenses [medium — operational]: Selling, general, and administrative expenses increased to $1.780 million from $1.688 million. While R&D expenses remained stable at $1.944 million, the overall operating expenses are substantial relative to current revenue.
• Significant Lease Obligations [medium — financial]: The company entered into a new lease for a 17,628 sq ft facility with total contractual base rent obligations of approximately $3.0 million. This represents a significant future financial commitment that will impact cash flow.
• Commercialization Challenges [high — market]: The company is actively commercializing its AMS Technology through subsidiaries. Success is dependent on market adoption, competition, and the ability of these subsidiaries to generate sustainable revenue beyond grants.

Industry Context

ASTROTECH Corp operates in the biotechnology and technology sector, focusing on developing and commercializing its AMS Technology. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on a mix of grant funding, venture capital, and strategic partnerships to finance operations during the development phase.

Regulatory Implications

As a technology and potentially medical device company, ASTC may be subject to various regulatory approvals and compliance requirements depending on the specific applications of its AMS Technology. Failure to meet these standards could result in delays, fines, or inability to bring products to market.

What Investors Should Do

1. Monitor cash burn rate closely.
2. Evaluate the sustainability of grant revenue.
3. Analyze SG&A expense trends.
4. Assess progress in commercialization efforts.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported $297,000 in revenue, a significant increase driven by grant and training revenue, but also a widened net loss of $3.465 million and a decrease in cash to $2.646 million.
• 2025-06-30: End of Q2 2025 — Company had $3.100 million in cash and cash equivalents and $21.975 million in total current assets.
• 2024-09-30: End of Q3 2024 — Reported $34,000 in revenue and a net loss of $3.278 million.
• 2025-11-11: Common Shares Outstanding Date — Reported 1,758,953 common shares outstanding, relevant for per-share calculations.

Glossary

Grant Revenue

Revenue received from government grants or other non-commercial funding sources, often tied to specific research or development projects. (A significant, new driver of revenue for ASTC in Q3 2025, highlighting reliance on non-operational funding.)

Operating Lease Right-of-Use Assets

An asset recognized under accounting standards for the right to use an asset (like a building) over the lease term. (Represents the value of the company's leased facilities, including the new Metric Facility, impacting the balance sheet.)

Accumulated Deficit

The cumulative net losses of a company since its inception, representing the total amount by which losses have exceeded profits. (ASTC has a substantial accumulated deficit of $254.335 million, indicating a history of unprofitability.)

Contract Asset

Represents a company's right to consideration in exchange for goods or services that the company has transferred to a customer. It arises when the company has performed but has not yet an unconditional right to payment. (ASTC reported $0 contract assets, suggesting no significant revenue recognized without an unconditional right to payment.)

Weighted average common shares outstanding

The average number of common shares outstanding over a period, used for calculating earnings per share. (Used to calculate the net loss per common share, which was -$2.07 for Q3 2025.)

Year-Over-Year Comparison

ASTROTECH Corp reported a dramatic 773.5% increase in revenue for Q3 2025 compared to Q3 2024, primarily due to new grant and training revenue streams. However, this top-line growth was overshadowed by a widening net loss of $3.465 million, up from $3.278 million. Operating expenses, particularly SG&A, saw an increase, while cash reserves and total current assets declined, indicating a worsening financial condition despite revenue growth.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share ASTC NASDAQ Sto

Filing Documents

• astc20250930_10q.htm (10-Q) — 949KB
• ex_888107.htm (EX-19.1) — 53KB
• ex_862690.htm (EX-31.1) — 13KB
• ex_885630.htm (EX-31.2) — 13KB
• ex_862692.htm (EX-32.1) — 6KB
• logo2.jpg (GRAPHIC) — 7KB
• logo.jpg (GRAPHIC) — 11KB
• 0001437749-25-034858.txt ( ) — 5628KB
• astc-20250930.xsd (EX-101.SCH) — 54KB
• astc-20250930_cal.xml (EX-101.CAL) — 45KB
• astc-20250930_def.xml (EX-101.DEF) — 326KB
• astc-20250930_lab.xml (EX-101.LAB) — 313KB
• astc-20250930_pre.xml (EX-101.PRE) — 364KB
• astc20250930_10q_htm.xml (XML) — 873KB

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 19 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 25 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 25 PART II: OTHER INFORMATION 26 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 26 ITEM 1A.

RISK FACTORS

RISK FACTORS 26 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 27 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 27 ITEM 4. MINE SAFETY DISCLOSURES 27 ITEM 5. OTHER INFORMATION 27 ITEM 6. EXHIBITS 28 2 Table of Contents

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

ITEM 1. Condensed Consolidated Financial Statements ASTROTECH CORPORATION AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except share and per share data) September 30, June 30, 2025 2025 (Unaudited) (Note) Assets Current assets Cash and cash equivalents $ 2,646 $ 3,100 Short-term investments 11,290 15,108 Accounts receivable 354 485 Contract Asset — — Inventory, net: Raw materials 2,342 2,194 Work-in-process 286 425 Finished goods 454 310 Prepaid expenses and other current assets 821 353 Total current assets 18,193 21,975 Property and equipment, net 2,606 2,395 Intangible asset, net 50 48 Operating lease right-of-use assets, net 2,044 2,225 Other assets, net 347 346 Total assets $ 23,240 $ 26,989 Liabilities and stockholders ' equity Current liabilities Accounts payable $ 613 $ 1,066 Payroll related accruals 534 529 Accrued expenses and other liabilities 328 451 Lease liabilities, current 384 405 Total current liabilities 1,859 2,451 Accrued expenses and other liabilities, net of current portion 134 164 Lease liabilities, net of current portion 2,160 2,274 Total liabilities 4,153 4,889 Commitments and contingencies (Note 14) Stockholders ' equity Convertible preferred stock, $ 0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at September 30, 2025, and June 30, 2025 — — Common stock, $ 0.001 par value, 250,000,000 shares authorized at September 30, 2025, and June 30, 2025, respectively; 1,769,269 shares issued at September 30, 2025, and June 30, 2025, respectively; 1,758,953 and 1,701,729 shares outstanding at September 30, 2025, and June 30, 2025, respectively 190,643 190,643 Treasury shares, 10,316 at September 30, 2025, and June 30, 2025, respectively ( 119 ) ( 119 ) Additional paid-in capital 83,614 83,310 Accumulated deficit ( 254,335 ) ( 250,870 ) Accumulated other comprehensive l

View Full Filing

View this 10-Q filing on SEC EDGAR